Tag: PhD2

Poster-Imaging

Influence of Imaging Parameters on MRI Contrast Using Qualitymetrix

Background: Acquiring brain magnetic resonance images (MRI) with sufficient tissue contrast is important for supporting diagnosis and...

Read More

Poster-Imaging

Compliance of a Real-World Dataset with the CMSC 2018 Guidelines

Background: Acquiring brain magnetic resonance images (MRI) in a standardized way, following CMSC guidelines, increases image consistency...

Read More

Poster-Disease-modifying Therapy

Efficacy of Ofatumumab on Microglial Activity in Patients with Relapsing Forms of Multiple Sclerosis: Interim Analysis

INTRODUCTION Ofatumumab, a fully-human anti-CD20 monoclonal antibody, is indicated for the treatment of relapsing forms of multiple...

Read More

Poster-Epidemiology and Genetics

Demographic and Clinical Associations with Neuromyelitis Optica Spectrum Disorder in an Academic Medical Center

Background: Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare, inflammatory CNS syndrome, which, left untreated, may result in...

Read More

Poster-Epidemiology and Genetics

Baseline Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients Enrolling in the US-Based Corrona MS Registry

Background: An estimated 85% of persons with multiple sclerosis (MS) present with relapsing-remitting (RRMS) disease. There are few large...

Read More

Poster-Family and Caregivers

Profiles of Resilience Among MS Care Partners

Background: Psychological resilience may play an important role in protecting multiple sclerosis (MS) care-partners from the negative...

Read More

Poster-Disease-modifying Therapy

The Benefits of Azathioprine in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Systematic Review and Meta-Analysis

Background: MOGAD is an emerging inflammatory demyelination disorder of the central nervous system. AZA is one of the commonly used...

Read More

Poster-Disease-modifying Therapy

Baseline MRI Predictors of Cognitive Processing Speed in Participants with Secondary Progressive Multiple Sclerosis from the Phase 3 Expand Study

Background: Siponimod showed beneficial effects on magnetic resonance imaging (MRI) lesion activity, total brain and gray matter (GM)...

Read More

Poster-Disease-modifying Therapy

COVID-19 Prevention Behaviors and PCR Testing Among MS Patients Treated with Different Dmts: Survey Data from MS Paths

Background: Emerging data from people with multiple sclerosis (PwMS) suggest that some disease-modifying therapies (DMTs) may impact the...

Read More

Poster-Disease-modifying Therapy

Assessing the Impact of Fingolimod Adherence on Relapse and Costs Using Marginal Structural Models

Background: Disease modifying therapies (DMTs) for relapsing MS are most effective when patients adhere to them as prescribed. Published...

Read More